Transcriptomics

Dataset Information

0

An orthotopic organoid-based model to track CD8⁺ T cell exhaustion dynamics in colorectal cancer.


ABSTRACT: Colorectal cancer (CRC) treatment represents a major clinical challenge, with immunotherapy providing durable responses in a minority of patients. A deeper understanding of CD8⁺ T cell exhaustion and its contribution to immune checkpoint inhibitor (ICI) responsiveness is essential for the development of more effective therapeutic strategies. Here, we established a syngeneic organoid-based orthotopic CRC mouse model by transplanting quadruple mutant Apc⁻/⁻KrasG12D/+Trp53R172H/⁻Smad4⁻/⁻ (AKPS) intestinal organoids into the rectal submucosa of immunocompetent mice. Single-cell transcriptomic profiling revealed that tumor-infiltrating CD8⁺ T cell phenotypes span a continuum of differentiation states, ranging from precursor exhausted (Tpex) to terminally exhausted (Tex) CD8+ cell subsets. In contrast, subcutaneous implants of AKPS were infiltrated by mixed CD4⁺ and CD8⁺ cell subsets, with CD8⁺ T cells exhibiting a markedly lower exhaustion profile, highlighting the limitations of heterotopic tumor models for studying antitumor immune responses. Functionally, CD8⁺ T cell depletion led to increased tumor burden in orthotopic AKPS implants, underscoring their antitumor activity. Importantly, anti-PD-1 treatment reduced tumor growth, demonstrating the responsiveness of this model to ICIs. Together, our findings establish the AKPS orthotopic CRC model as a powerful platform to dissect the molecular mechanisms of CD8⁺ T cell exhaustion and to preclinically evaluate novel immunotherapeutic interventions in CRC.

ORGANISM(S): Mus musculus

PROVIDER: GSE310071 | GEO | 2026/05/27

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-11-15 | GSE188711 | GEO
2020-05-01 | GSE148162 | GEO
2024-05-23 | GSE252358 | GEO
2015-09-08 | E-GEOD-72752 | biostudies-arrayexpress
2023-08-25 | E-MTAB-10607 | biostudies-arrayexpress
2026-04-21 | PXD063865 | Pride
2026-04-30 | PXD067417 | Pride
2026-04-21 | PXD070932 | Pride
2023-06-16 | MSV000092193 | MassIVE
2022-03-03 | PXD029507 | Pride